

Company:

"SOPHARMA" AD

Board of Directors:

**Ognian Donev, PhD
Vessela Stoeva
Alexander Chaushev
Ognian Palaveev
Ivan Badinski**

Executive Director:

Ognian Donev, PhD

Procurator:

Simeon Donev

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

Head of Legal Department

Alexander Yotov

Registered Office:

**Sofia
16, Iliensko Shousse Str.**

Lawyers:

**Adriana Baleva
Venelin Gachev
Ventsislav Stoev
Stefan Vachev**

Servicing Banks:

**Raiffeisenbank (Bulgaria) EAD
DSK Bank EAD
Eurobank and FG Bulgaria AD
ING Bank N.V.
UniCredit AD
Citibank N.A.
Cibank EAD**

Auditors:

Baker Tilly Clitou and Partners OOD

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME**

for the period ended on 30 September 2021

	Notes	2021 BGN'000	2020 BGN'000
Revenue	3	137 778	140 845
Other operating income/(losses), net	4	2 901	3 004
Changes in inventories of production and work in progress		2 924	12 960
Raw materials and consumables used	5	(44 603)	(52 936)
Hired services expense	6	(24 131)	(25 217)
Employee benefits expense	7	(34 537)	(38 080)
Depreciation and amortisation expense	13,14	(13 207)	(13 706)
Other operating expenses	8	(2 125)	(6 369)
Profit from operations		25 000	20 501
Impairment of non-current assets	9	(2 050)	(1 072)
Finance income	10	3 352	11 722
Finance costs	11	(1 442)	(7 366)
Finance income / (costs), net		1 910	4 356
Profit before income tax		24 860	23 785
Income tax expense		(2 452)	(1 651)
Net profit for the year		22 408	22 134
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Net change in the fair value of other long-term equity investments	18	66	(647)
(Loss)/Profit from remeasurement of property, plant and equipment, net		-	(41)
Income tax relating to items of other comprehensive income that will not be reclassified		-	4
Other comprehensive income for the year, net of tax	12	66	(684)
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		22 474	21 450
Basic earnings per share	26	0,18	0,18

The accompanying notes on pages 5 to 134 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF FINANCIAL POSITION**

as at 30 September 2021

	Notes	30 September 2021 BGN'000	31 December 2020 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	13	201 065	211 681
Intangible assets	14	4 248	4 143
Investment property	15	48 032	44 759
Investments in subsidiaries	16	83 908	86 809
Investments in associates and joint ventures	17	10 796	6 062
Other long-term equity investments	18	11 896	11 607
Long-term receivables from related parties	19	51 276	59 725
Other long-term receivables	20	11 079	11 105
		422 300	435 891
Current assets			
Inventories	21	67 514	68 160
Receivables from related parties	22	89 046	114 169
Trade receivables	23	23 183	18 382
Loans granted to third parties	24 (a)	690	3 903
Other receivables and prepayments	24 (b)	6 652	6 057
Cash and cash equivalents	25	5 041	3 776
		192 126	214 447
TOTAL ASSETS		614 426	650 338
EQUITY AND LIABILITIES			
EQUITY			
Basic share capital		134 798	134 798
Treasury shares		(37 735)	(33 656)
Reserves		431 116	408 807
Retained earnings	26	27 204	27 039
		555 383	536 988
LIABILITIES			
Non-current liabilities			
Long-term bank loans	27	7	15
Deferred tax liabilities	28	5 182	5 358
Government grants	29	4 112	4 427
Liabilities under leasing contracts	30	933	1 533
Retirement benefit obligations	31	4 995	4 758
		15 229	16 091
Current liabilities			
Short-term bank loans	32	23 616	73 335
Current portion of long-term bank loans	27	9	2 404
Trade payables	33	6 651	7 218
Payables to related parties	34	1 802	1 273
Tax payables	35	1 535	2 092
Payables to personnel and for social security	36	7 421	7 507
Other current liabilities	37	2 780	3 430
		43 814	97 259
TOTAL LIABILITIES		59 043	113 350
TOTAL EQUITY AND LIABILITIES		614 426	650 338

The accompanying notes on pages 5 to 132 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF FINANCIAL POSITION**

for the period ended on 30 September 2021

	Notes	2021 BGN'000	2020 BGN'000
Cash flows from operating activities			
Cash receipts from customers		173 106	124 853
Cash paid to suppliers		(74 646)	(90 885)
Cash paid to employees and for social security		(33 540)	(37 169)
Taxes paid (except income taxes)		(6 496)	(7 034)
Taxes refunded (except income taxes)		1 260	3 286
(Paid) / refunded income taxes, net		(3 155)	(3 568)
Paid interest and bank charges on working capital loans		(905)	(1 285)
Exchange rate differences, net		(98)	(171)
Other proceeds/(payments), net		(1 278)	(1 310)
Net cash flows from operating activities		54 248	(13 283)
Cash flows from investing activities			
Purchases of property, plant and equipment		(3 087)	(4 610)
Proceeds from sales of property, plant and equipment		93	1 179
Purchases of intangible assets		(498)	(143)
Purchased of investment property		(4 201)	(2 045)
Proceeds from sales of investment properties		1 073	-
Purchases of shares in associates		(3 100)	-
Proceeds from sale of shares in associates		354	1
Purchases of long-term equity investments		(2 085)	(2 173)
Proceeds from sales of long-term equity investments		2 008	53
Purchases of shares and stakes in subsidiaries		(313)	(3 276)
Proceeds from sale of shares and stakes in subsidiaries		1 331	-
Loans granted to related parties		(3 200)	(4 440)
Loan repayments by related parties		9 813	38 509
Loans granted to other companies		(500)	(978)
Loan repayments by other companies		3 698	1 372
Interest received on granted loans		2 339	1 991
Dividend proceeds from investments in subsidiaries		594	9 138
Dividend proceeds from long-term equity investments		268	38
Proceeds from charges under guarantees		48	-
Net cash flows used in investing activities		4 635	34 616
Cash flows from financing activities			
Proceeds from long - term bank loans		-	28
Repayment of long-term bank loans		(2 411)	(5 408)
(Repayment) / Proceeds from short-term bank loans (overdraft), net		(49 665)	(769)
Interest and charges paid under investment purpose loans		(80)	(99)
Treasury shares		(4 079)	(262)
Proceeds from sales of treasury shares		-	805
Dividends paid		(11)	(14 952)
Payments under leases contracts		(1 436)	(1 449)
Government grants received		64	87
Net cash flows from (used in) financial activities		(57 618)	(22 019)
Net decrease in cash and cash equivalents		1 265	(686)
Cash and cash equivalents at 1 January		3 776	3 959
Cash and cash equivalents at 30 September	25	5 041	3 273

The accompanying notes on pages 5 to 132 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

for the period ended on 30 September 2021

	Notes	Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Additional reserves	Retained earnings	Total equity
		BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000
Balance at 1 January 2020	26	134 798	(34 142)	59 297	22 040	2 873	298 339	39 439	522 644
Changes in equity for 2020									
Effects of sold and repurchased treasury shares, incl:		-	486	-	-	-	-	(144)	342
- sold repurchased shares		-	949	-	-	-	-	(144)	805
- acquisition of treasury shares		-	(463)	-	-	-	-	-	(463)
Distribution of profit for:		-	-	4 038	-	-	23 257	(41 125)	(13 830)
- reserves		-	-	4 038	-	-	23 257	(27 295)	-
- dividends from profit for 2019		-	-	-	-	-	-	(8 798)	(8 798)
- 6-month dividends on 2020 profit		-	-	-	-	-	-	(5 032)	(5 032)
Total comprehensive income for the year, incl:		-	-	-	(37)	(637)	-	28 506	27 832
- net profit for the year		-	-	-	-	-	-	28 664	28 664
- other comprehensive income, net of taxes		-	-	-	(37)	(637)	-	(158)	(832)
Transfer to retained earnings		-	-	-	(409)	46	-	363	-
Balance at 31 December 2020	26	134 798	(33 656)	63 335	21 594	2 282	321 596	27 039	536 988
Changes in equity for 2021									
Effect of pay back treasury shares incl:		-	(4 079)	-	-	-	-	-	(4 079)
- sold repurchased shares		-	-	-	-	-	-	-	-
- acquisition of treasury shares		-	(4 079)	-	-	-	-	-	(4 079)
Distribution of profit for:		-	-	2 866	-	-	20 985	(23 851)	-
- reserves		-	-	2 866	-	-	20 985	(23 851)	-
Total comprehensive income for the year, incl:		-	-	-	-	66	-	22 408	22 474
- net profit for the year		-	-	-	-	-	-	22 408	22 408
- other comprehensive income, net of taxes		-	-	-	-	66	-	-	66
Transfer to retained earnings		-	-	-	(346)	(1 262)	-	1 608	-
Balance at 30 September 2021	26	134 798	(37 735)	66 201	21 248	1 086	342 581	27 204	555 383

The accompanying notes on pages 5 to 132 form an integral part of the individual financial statements.

Executive Director:
Ognian Donev, PhD

Finance Director:
Boris Borisov

Chief Accountant:
Jordanka Petkova